Annals of Oncology 14:843-848, 2003
© 2003 European Society for Medical Oncology
Original Paper |
Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy
1 Divisione Oncologia Medica, Ospedale Policlinico, Perugia; 2 Unità di Statistica Medica, Dip. Medicina Interna e Salute Pubblica, Università, L’Aquila; 3 Dipartimento Medicina Interna e Scienze Oncologiche, Università, Perugia; 4 Divisione Oncologia Medica, Cosenza; 5 Oncologia Preventiva, Centro di Riferimento Oncologico, Aviano, Pordenone; 6 Divisione Oncologia Medica, Policlinico, Modena; 7 Divisone Oncologia Medica, Ospedale Borgo Trento, Verona; 8 Dipartimento di Medicina, Istituto Europeo di Oncologia, Milan, Italy
Received 30 October 2002; revised 14 January 2003; accepted 24 February 2003
Background:
Evidence-based guidelines, consensus conferences and experts’ opinion are rarely promptly transferred to patient care. We audited prescriptions of adjuvant systemic therapies for Italian breast cancer patients and compared them with recommendations of an International Consensus Panel.
Patients and methods:
Disease characteristics and adjuvant therapies for 768 breast cancer patients referred to 87 Italian centers from 16 to 23 March 2000 were evaluated for adherence to the published recommendations.
Results:
Endocrine therapy was not prescribed for 102 of 541 patients (19%) with endocrine-responsive disease and for 22 of 45 patients (49%) with unknown hormonal receptor status. Instead, endocrine therapy was prescribed for 22 of 182 patients (12%) with endocrine-unresponsive disease. Adjuvant chemotherapy was prescribed for 98% of the patients. The type of chemotherapy was the cyclophosphamide, methotrexate, 5-fluorouracil regimen for 453 of 754 (60%), while 253 of 754 (34%) received an anthracycline-based regimen. The proportion of patients with anthracyclines increased with the number of involved axillary nodes and grading, and decreased with age. Endocrine therapy was administered to 482 of 768 (63%) and was mainly represented by an antiestrogen.
Conclusions:
Lack of adherence to evidence-based guidelines for adjuvant treatment of Italian breast cancer patients was as high as 19%. It might be wise for national health authorities to promote education on life-saving procedures, like adjuvant systemic treatments, in cancer medicine.
Key words: adjuvant therapies, breast carcinoma, drug utilization review, guidelines adherence, practice guidelines
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Merglen, H. M. Verkooijen, G. Fioretta, I. Neyroud-Caspar, V. Vinh-Hung, G. Vlastos, P. O. Chappuis, M. Castiglione, E. Rapiti, and C. Bouchardy Hormonal therapy for oestrogen receptor-negative breast cancer is associated with higher disease-specific mortality Ann. Onc., May 1, 2009; 20(5): 857 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Magai, N. S. Consedine, B. A. Adjei, D. Hershman, and A. Neugut Psychosocial Influences on Suboptimal Adjuvant Breast Cancer Treatment Adherence Among African American Women: Implications for Education and Intervention Health Educ Behav, December 1, 2008; 35(6): 835 - 854. [Abstract] [PDF]
|
|
|
|
|
|
M. E. Cazzaniga, G. Mustacchi, P. Pronzato, A. De Matteis, F. Di Costanzo, I. Floriani, and On behalf of the NORA Study Group Adjuvant treatment of early breast cancer: do the St Gallen recommendations influence clinical practice? Results from the NORA study Ann. Onc., December 1, 2007; 18(12): 1976 - 1980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Mustacchi, M. Cazzaniga, P Pronzato, A De Matteis, F Di Costanzo, I Floriani, and On behalf of the NORA Study Group Breast cancer in elderly women: a different reality? Results from the NORA study Ann. Onc., June 1, 2007; 18(6): 991 - 996. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cazzaniga, G Mustacchi, P Pronzato, A De Matteis, F Di Costanzo, I Floriani, and On behalf of the NORA Study Group Adjuvant systemic treatment of early breast cancer: the NORA study Ann. Onc., September 1, 2006; 17(9): 1386 - 1392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 International Breast Cancer Study Group Tamoxifen After Adjuvant Chemotherapy for Premenopausal Women With Lymph Node-Positive Breast Cancer: International Breast Cancer Study Group Trial 13-93 J. Clin. Oncol., March 20, 2006; 24(9): 1332 - 1341. [Abstract] [Full Text] [PDF]
|
|